Compare Roblox Corp (RBLX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roblox Corp vs Recursion Pharmaceuticals Inc — how do they compare? Roblox Corp trades at $48.07 (market cap $32.52B), while Recursion Pharmaceuticals Inc trades at $4.41 (market cap $2.14B). The key difference: Roblox Corp is far larger — about 15.2× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Roblox Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Roblox Corp for 93 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| RBLX | RXRX | |
|---|---|---|
Market Cap | $32.52B | $2.14B |
Volume | 14,552,045 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $138.56 | $6.79 |
52-Week Low | $35.54 | $2.84 |
Typical Hold Time | 93 Days | 23 Days |
Enterprise Value | $31.34B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RBLX trades at $48.09, up 3.62% today, showing strong momentum despite a bearish technical signal. The stock has beaten earnings expectations for three consecutive quarters, with revenue growing from $2.2B in 2022 to $4.9B in 2025. However, the company remains unprofitable with a net income margin of -17.61% and negative ROE of -396.28%. Recent news highlights mixed sentiment, including a Jefferies downgrade to Underperform on September 28, 2026, citing concerns about bookings growth, offset by optimism around AI tools unveiled at the developer conference.
The outlook for RBLX hinges on balancing robust revenue growth against persistent losses. The consensus price target of $50.85 suggests modest upside, but high P/B of 213.94 and negative profitability metrics pose risks. Key opportunities include AI-driven creator tools and expanding user engagement, while threats involve booking deceleration and competitive pressure. Investors should weigh the company's growth trajectory against its path to profitability.
RXRX trades at $4.36, up 2.11% today, with technical indicators showing a bullish trend. The company reported Q3 2026 revenue of $54 million but continues to post significant losses with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche are expanding its AI-driven drug pipeline, though the stock faces high short interest and substantial cash burn from operations.
The outlook remains speculative given persistent losses and high valuation multiples (P/S 37.14), but analyst consensus leans positive with 40% buy ratings. Key risks include execution on drug development timelines and dependence on financing activities to fund operations. Upside potential hinges on successful clinical milestones from its expanding pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
